These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 23226020)
1. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles. Rangger C; Helbok A; von Guggenberg E; Sosabowski J; Radolf T; Prassl R; Andreae F; Thurner GC; Haubner R; Decristoforo C Int J Nanomedicine; 2012; 7():5889-900. PubMed ID: 23226020 [TBL] [Abstract][Full Text] [Related]
2. Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles. Rangger C; Helbok A; Sosabowski J; Kremser C; Koehler G; Prassl R; Andreae F; Virgolini IJ; von Guggenberg E; Decristoforo C Int J Nanomedicine; 2013; 8():4659-71. PubMed ID: 24353415 [TBL] [Abstract][Full Text] [Related]
3. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848 [TBL] [Abstract][Full Text] [Related]
4. Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Liu Z; Liu S; Wang F; Liu S; Chen X Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1296-307. PubMed ID: 19296102 [TBL] [Abstract][Full Text] [Related]
5. Ligands for mapping alphavbeta3-integrin expression in vivo. Schottelius M; Laufer B; Kessler H; Wester HJ Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579 [TBL] [Abstract][Full Text] [Related]
6. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). Wu Z; Li ZB; Chen K; Cai W; He L; Chin FT; Li F; Chen X J Nucl Med; 2007 Sep; 48(9):1536-44. PubMed ID: 17704249 [TBL] [Abstract][Full Text] [Related]
7. Development of High-Functionality and -Quality Lipids with RGD Peptide Ligands: Application for PEGylated Liposomes and Analysis of Intratumoral Distribution in a Murine Colon Cancer Model. Suga T; Kato N; Hagimori M; Fuchigami Y; Kuroda N; Kodama Y; Sasaki H; Kawakami S Mol Pharm; 2018 Oct; 15(10):4481-4490. PubMed ID: 30179010 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. Su ZF; Liu G; Gupta S; Zhu Z; Rusckowski M; Hnatowich DJ Bioconjug Chem; 2002; 13(3):561-70. PubMed ID: 12009947 [TBL] [Abstract][Full Text] [Related]
9. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975 [TBL] [Abstract][Full Text] [Related]
10. Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide. Dijkgraaf I; Terry SY; McBride WJ; Goldenberg DM; Laverman P; Franssen GM; Oyen WJ; Boerman OC Contrast Media Mol Imaging; 2013; 8(3):238-45. PubMed ID: 23606427 [TBL] [Abstract][Full Text] [Related]
11. MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides. Jacobson O; Zhu L; Niu G; Weiss ID; Szajek LP; Ma Y; Sun X; Yan Y; Kiesewetter DO; Liu S; Chen X Mol Imaging Biol; 2011 Dec; 13(6):1224-33. PubMed ID: 21161690 [TBL] [Abstract][Full Text] [Related]
12. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers. Shi J; Kim YS; Chakraborty S; Zhou Y; Wang F; Liu S Amino Acids; 2011 Nov; 41(5):1059-70. PubMed ID: 20052508 [TBL] [Abstract][Full Text] [Related]
13. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640 [TBL] [Abstract][Full Text] [Related]
14. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells. Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336 [TBL] [Abstract][Full Text] [Related]
15. Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Yang J; Guo H; Miao Y Nucl Med Biol; 2010 Nov; 37(8):873-83. PubMed ID: 21055617 [TBL] [Abstract][Full Text] [Related]
16. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129 [TBL] [Abstract][Full Text] [Related]
17. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Chen X; Park R; Shahinian AH; Bading JR; Conti PS Nucl Med Biol; 2004 Jan; 31(1):11-9. PubMed ID: 14741566 [TBL] [Abstract][Full Text] [Related]
19. Dual receptor-targeting ⁹⁹mTc-labeled Arg-Gly-Asp-conjugated Alpha-Melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Xu J; Yang J; Miao Y Nucl Med Biol; 2015 Apr; 42(4):369-74. PubMed ID: 25577037 [TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent. Zhang X; Chen X Appl Radiat Isot; 2007 Jan; 65(1):70-8. PubMed ID: 17011200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]